Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PragmaTIL: TIL therapy with ANV600 versus high-dose IL-2 in advanced melanoma, NSCLC, and cervical cancer
NL-OMON58901Phase 2Not yet recruiting
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- May 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ANV600, aldesleukin and GC101 TIL + pembrolizumab in melanoma, non-small cell lung cancer (NSCLC) and Cervical Cancer (CC) (3 arms), sponsored by Vall d'Hebron Institute of Oncology. Primary endpoints: Mean number of predefined grade 3 or higher relevant adverse events and Change in PRO-CTCAE composite score. Planned start May 2024; status: not yet recruiting.
02
Drugs
ANV600aldesleukinGC101 TIL + pembrolizumab
03
Conditions
melanomanon-small cell lung cancer (NSCLC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NL-OMON58901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58901.